| |
July 18-19, 2023 | Jersey City, NJ This is the only communications event for peer learning and networking exclusively for the life science community. Save $500, Register Today!
|
|
Today's Big NewsApr 6, 2023 |
|
Tuesday, April 11, 2023 | 12pm ET / 9am PT In this webinar we will guide you along the scientific data journey where you can discover smart ways to get from raw data to insights and how to achieve an automated, interconnected lab with data liquidity across the organization. Register now.
|
|
| By Angus Liu Drugmakers often dream about being the sole player in a therapeutic area. But for AstraZeneca, the lack of rival success stories may mean increased regulatory scrutiny for its new treatment proposal for ovarian cancer. |
|
|
|
By Conor Hale After reversing course on a SPAC deal last year, cardiac diagnostic developer HeartFlow has picked up what could hardly be considered a consolation prize. |
By Nick Paul Taylor Quince Therapeutics is trying to make itself a less appetizing bite for potential buyers as it works to fend off an unsolicited buyout bid from Echo Lake Capital. The “poison pill” is intended to deter investors from accumulating stock on the open market and will kick in once they buy a set percentage of the shares. |
By Kevin Dunleavy In U.S. District Court, Pfizer has prevailed over five collection companies which sought to bring a potential class action lawsuit alleging that Pfizer illegally induced patients to a select group of drugs. |
|
Monday, April 24, 2023 | Boston, Massachusetts (and online) Intra-Target Microdosing (ITM) is a First-in-Human drug development approach that administers a drug microdose into a small target, generating therapeutic-level exposures in it and microdose exposures elsewhere, thus enabling collection of biomarkers. Join Us!
|
|
By Andrea Park Almost exactly three years after taking on the role, Ken Reali has stepped down from his post as chief executive of Bioventus. |
By Max Bayer AbbVie is revising down its earnings forecast for the year due to a $150 million IPR&D charge. The company's original earnings projections presented in February were already lower than Wall Street's projections. |
By Zoey Becker In yet another TAF/TDF drug lawsuit for Gilead Sciences, the company faces claims from two plaintiffs that it caused injuries with its older tenofovir products while shelving a safer generation of new products. |
By Nick Paul Taylor Exelixis is standing its ground in the face of a full-throated attack by an activist investor, defending its record in response to accusations that it has presided over an undisciplined and incoherent R&D model. |
By Andrea Park More than a decade after it first became available to help patients hospitalized with spinal cord injuries breathe more naturally than they can with a ventilator, Synapse Biomedical’s diaphragm pacing system is, fittingly enough, picking up the pace. |
By Gabrielle Masson Takeda is moving away from early R&D work in the AAV gene therapy and rare hematology spaces, with an unknown number of employees set to “transition out” of the pharma. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
|
| Tuesday, April 11, 2023 | 1pm ET / 10am PT Achieving interoperability in healthcare can be a daunting task, but sharing and collaborating with data has the potential to generate better clinical outcomes, enable new care models, and enhance patient experience. Join healthcare industry experts for this important roundtable discussion to learn more. Register now. |
|
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
